Form D · Private Equity Fund

Avego Bioscience Capital, L.P.

Alpharetta, GA · CIK 0001910611

Offering snapshot reported Mar 7, 2025 · SEC filing

Reported sold: $68.7M
Investors reported: 18
Minimum accepted: $0
First sale: Jan 12, 2021

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$50,905,344 → $68,741,447
Reported investors19 → 18

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 7, 2025	Amendment	$68,741,447	$17,836,103vs Mar 7, 2024	18	SEC filing
Mar 7, 2024	Amendment	$50,905,344	$1,054,564vs Mar 9, 2023	19	SEC filing
Mar 9, 2023	Amendment	$49,850,780	$29,068,255vs Mar 15, 2022	19	SEC filing
Mar 15, 2022	Initial	$20,782,525	No comparison	14	SEC filing

Offering details

Securities: Equity, Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $0 (estimated)
Finders' fees: $0 (estimated)
Form D file number: 021-437251

Due to a clerical error, the total amount of investors reported in this Form D amendment is lower than the total reported in the Fund's last Form D amendment filing.

Source: Form D, filed Mar 7, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

AVEGO BIOSCIENCE CAPITAL, L.P.

Investment adviser: AVEGO MANAGEMENT, LLC

Gross asset value: $92.4M
Beneficial owners: 19
ADV minimum commitment: $0

Reported in Form ADV on Mar 31, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator NAV CONSULTING INC. OAKBROOK TERRACE, Illinois, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor COHNREZNICK LLP PARSIPPANY, New Jersey, United States

Custodian BTIG, LLC SAN FRANCISCO, California, United States Related to adviser: No

Custodian GOLDMAN SACHS & CO. LLC NEW YORK, New York, United States Related to adviser: No

Custodian JPMORGAN CHASE BANK, NATIONAL ASSOCIATION NEW YORK, New York, United States Related to adviser: No

Prime broker BTIG, LLC SAN FRANCISCO, California, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

COHNREZNICK LLP
PCAOB 596

BTIG, LLC
SEC 8-65473

GOLDMAN SACHS & CO. LLC
SEC 8-129

JPMORGAN CHASE BANK, NATIONAL ASSOCIATION
LEI 7H6GLXDRUGQFU57RNE97

BTIG, LLC
CRD 122225 · SEC 8-65473

Filing source

Form ADV 2089033 · Mar 31, 2026 · Schedule D 7.B.(1), fund 805-3322422289

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Avego Bioscience Capital Gp, Llc	Executive, Promoter
Avego Management, Llc	Executive, Promoter
Velan Capital Invesment Management Lp	Executive, Promoter

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

100 North Main St Suite 301
Alpharetta, GA, 30009